LMAO !!!!! He was saying it will never get to 3 dollars..... Europe news tonight is only out done by the FDA re-evaluation coming. (1) European initiatives look very promising for Iclusig; this work will likely benefit very well both patients and the company; (2) uncertainty prevails in US over Iclusig return to market and differences between Ariad and FDA remain a very difficult barrier to surmount; (3) Clackson's public contesting of FDA change in methods of determination of adverse events was striking and hints at the level of disagreement, frustration, and anger among Ariad scientists and management with the FDA; (4) refocus of R&D on most promising candidates is encouraging, but sadly, limits innovation opportunities on other fronts; (5) interesting developments in Japan; (6) Europe, Uk, Germany , Australia sales – they reduced dose and took an asprin…… 600 DRs prescribed 1000 orders. ; (7) Narrowing business plan- cost cutting measures now in place are rightly based on most conservative financial outlook; terribly unfortunate for the company and its employees, but necessary part of this "crisis management" at this stage. 8) stock down 88 and upside out ways downside. 9) Stock could rocket with partner of FDA progress 9) breast cancer activity. 10) Marketing in 15 countries. 11) the company will be presenting some data at ASH that could help us clarify the risk/reward of ponatinib and possibly offer a chance at salvation for ARIAD Pharmaceuticals.
I own both of them as well #$%$ other BIOTECHNOLOGY stocks. I also have two different biotech funds. Who can pass up these type of returns beside a holywallstreet clown.
We tried to tell shorts the BIOTECH funds want a 60% return next year also. GOOD stocks like this is their only way to do it again next year.
Shorts have got to be worried as trying to get shares cheap. Their days are numbered. Their only recourse is to say 1) I am not stupid only foolish for not covering 50% lower. 2) I like giving up my 60% gains. 3) I was in a drunken stubbier and couldn't find my computer. 4) MY lies and tricks might work with 100 negative post in a hour. 5) Bottom fishing is stupid???????Short trends may not last or will they as conditions improve for the company??????? 3.Valuation comparables for this company are/aren't hard to determine. 6) There are three competitors: Ariosa, Illumina and Natera. Ariosa and Natera are both private. Illumina is not particularly helpful, considering how immaterial Verifi is to their results. The calculation I use is enterprise value as a multiple of 2014 revenues. IF we are priced any way near Illumina this could more then double....................... WHO reads ALPHA any way!!!!!!!!!!!!!!!!!!!!!!!!
people will be digging into this stock and asking , why did this fell so hard ???? WHY is it working in Europe with out complications?????? Can it be made safe without clots.......... MOST IMPORTANTLY!!!!!!!! are we over reacting???????? The Bio -Pharma industry funds are up again after some resistance. They have out performed the other markets. NOW
had to do that shorty
Cover fool. Maxim raised its price target for Intellipharmaceutics to $9 after the FDA approved the company’s generic version of Focalin. Brean's Jonathan Aschoff "believes the sales generated from generic Focalin XR should significantly enhance the company's financial position." Price target is $7. 10) cash and cash equivalents totaled $2.4 million In July 2013, Shorts are over extended. The news is huge and you will see the second buying wave next week.
Cover fools and U CANT read. 1)))) The Company's patented Hypermatrix(TM) technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. This is a novel and generic controlled-release and targeted-release oral solid dosage drugs delivery system 2))) FDA FDA Issues Final Approval of 15 mg, With 180 Days of Exclusivity, and 30 mg; and The company's strategy in the pharmaceutical space is to turn currently marketed drugs that are developed for immediate release into patentable extended release drugs. The company is also currently working on new drug delivery technologies which could attain a large value if successfully brought to market. (((BINGO)))))))
3)) -- Tentative Approvals for the Company's 5, 10, 20 and 40 mg Strengths 4)) Commercial sale of these strengths will be launched immediately by the Company's commercialization partner in the United States Par Pharmaceutical, Inc. ("Par"). 5) generic version of Focalin XR(R) is a major milestone for the Company in several respects. A) a strong validation of our core drug development B) partner with an established and well-regarded pharmaceutical company C) production through commercialization in the United States D) generate our first US revenues i) By virtue of being the first-filer in the 15mg dose, IPCI will have 180 days of exclusivity of generic sales.
6)) MORE TO COME ! Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of product candidates in various stages of development, including Abbreviated New Drug Applications ("ANDAs") filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.
7) Pipeline- Intellipharmaceutics also has New Drug Application 505(b)(2) product candidates in its development pipeline. These include Rexista(TM) oxycodone, an abuse-deterrent oxycodone, based on its proprietary novel Point Of Divergence Drug Delivery System ("nPODDDS(TM)") and a pregabalin extended-release ("Regabatin(TM) XR").
• 8) Intellipharmaceutics approval should enhance cash position, says Brean Capital 9) UPGRADES! Maxim raised its price target for Intellipharmaceutics to $9 after the FDA approved the company’s generic version of Focalin. Brean's Jonathan Aschoff "believes the sales generated from generic Focalin XR should significantly enhance the company's financial position." Price target is $7. 10) cash and cash equivalents totaled $2.4 million In July 2013, Intellipharmaceutics announced an update on its Rexista(TM) oxycodone development program. The results from physico-chemical tests to assess abuse-deterrent properties of its Rexista(TM) oxycodone suggested that intact, pulverized or microwaved product with or without various solvents and temperatures, will be difficult to extract through inhalation, injection, chewing or licking. Results of a successful Phase I clinical trial suggested that the technology in the Company's formulation of Rexista(TM) oxycodone does not interfere with the bioavailability of oxycodone as compared to OxyContin(R).
• IPCI lead product (at this time), is a generic of Focalin XR, is partnered with Par Pharmaceutical Inc. Par Pharmaceutical Inc. markets generic drugs and innovative proprietary pharmaceuticals for specialty markets. Under the agreement, Par is to pay IntelliPharmaCeutics 15 million dollars upon approval, and royalties that are expected to be around 40 million per year. This will bring the company into profitability.
Rexista™ Technology Platform Rexista™ provides deterrence against intentional drug abuse and unintentional dose dumping.
Hypermatrix Technology Platform
"IntelliFoam™" The IntelliFoam™[ technology is based on the drug active being embedded in, separately from a syntactic foam substrate, the properties of which are used to modulate the release of the drug active, that is embedded in a resin polymer matrix.
IntelliGITransporter™ The IntelliGITransporter™ consists of an active drug immobilized in a homogeneous matrix structure. A precise choice of mix ratios, polymers, and other ingredients imparts characteristics that protects the drug composition from mechanical degradation due to digestion, and/or from chemical degradation in the acidic stomach environment, and ensures that this technology allows control of release as well as releasing the medication at certain parts of the stomach or intestines without significant food effects or unintentional premature release of the entire drug dose. This is more useful for drug molecules with characteristics such as very low or very high potency, opiate analgesics, or susceptibility to acid degradation. It is also useful for products where a zero-order release profile is preferable.
IntelliMatrix™ The IntelliMatrix™ technology is a blend of several polymers; depending on the constituents of the blend and the manner in which these interact, the use of the blend with a drug allows the drug to be released at predetermined rates, while imparting protective characteristics to both the drug and the GIT. This is preferable for drugs which require precisely controlled first-order release profiles, where the amount released with time is dependent on one component like the amount of drug available for dissolution.
IntelliOsmotics™ The IntelliOsmotics™ technology is based upon the inclusion of multiple populations of polymers with distinct chemical bonding characteristics that set up a complex matrix of hydrophilic and hydrophobic domains. When the tablet or bead is in an aqueous environment, like gastric contents, a mixture of water-soluble polymer and drug core is surrounded by gel layer(s) of water-insoluble polymer. Osmotic pressure drives the drug out when solvent passes through the gel layer while the polymer molecules remain which permits control of the rate of release of the drug active by the variation of polymer ratios. This is useful for drug molecules that require controlled pseudo-first-order release profiles, where the rate of release is proportional to the amount available for dissolution while being proportional to one other component; however the effect of the amount of drug is overriding, so that the rate appears first-order. This type of release control can be useful when attempting to match difficult profiles for generic formulation.
IntelliPaste™ The IntelliPaste™ technology consists of blends of multiple polymers, oils, excipients and drug active(s) which result in a paste-in-a-capsule dosage form.
Why not at this price. ITS a deal and people know it. The shares will fly out the door. WE will take off.
Only bad , if you don't have enough long shares. this is going to go up hard soon. To the moon with OBAMA CARE and more coverage.